First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Barbara EichhorstCarsten U NiemannArnon P KaterMoritz FürstenauJulia von TresckowCan ZhangSandra RobrechtMichael GregorGunnar JuliussonPatrick ThorntonPhilipp B StaberTamar TadmorVesa LindströmCaspar da Cunha-BangChristof SchneiderChristian B PoulsenThomas IllmerBjörn SchöttkerThomas NösslingerAnn JanssensIlse ChristiansenMichael BaumannHenrik FrederiksenMarjolein van der KliftUlrich JägerMaria B L LeysMels HoogendoornKourosh LotfiHolger HebartTobias GaskaHarry KoeneLisbeth EnggaardJereon GoedeJosien C RegelinkAnouk WidmerFlorian SimonNisha De SilvaAnna-Maria FinkJasmin BahloKirsten FischerClemens-Martin WendtnerKarl A KreuzerMatthias RitgenMonika BrüggemannEugen TauschMark-David LevinMarinus van OersChristian GeislerStephan StilgenbauerMichael Halleknull nullPublished in: The New England journal of medicine (2023)
Venetoclax-obinutuzumab with or without ibrutinib was superior to chemoimmunotherapy as first-line treatment in fit patients with CLL. (Funded by AbbVie and others; GAIA-CLL13 ClinicalTrials.gov number, NCT02950051; EudraCT number, 2015-004936-36.).
Keyphrases